Original Publication Date: 1 July, 2015
Publication / Source: Future Oncology
Authors: Eric H Yang, Karol E Watson & Joerg Herrmann
For over half a century, the development of groundbreaking chemotherapeutic agents have resulted in prolonged survival outcomes and more treatment options for patients with hematologic and oncologic malignancies. In the shadow of these achievements, cardiovascular toxicities have been documented with most agents, including newer, so-called ‘targeted therapies’, which were initially considered to be have minimal cardiovascular adverse effects .